Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25959453 | 0.84 | DPP4 (0.45) | ALDH1A1NPC1DPP4KMT2AMEN1 | |
| SCHEMBL2606045 | 0.81 | ALDH1A1 (0.60) | ALDH1A1NPC1KMT2AMEN1PHGDH | |
| SCHEMBL25565796 | 0.81 | ALDH1A1 (0.56) | ALDH1A1NPC1KMT2AMEN1PHGDH | |
| SCHEMBL24491912 | 0.81 | ALDH1A1 (0.51) | ALDH1A1NPC1KMT2AMEN1PHGDH | |
| SCHEMBL24818614 | 0.80 | DPP4 (0.47) | ALDH1A1DPP4KMT2AMEN1KDM4E | |
| SCHEMBL24323532 | 0.80 | L3MBTL1 (0.48) | ALDH1A1DPP4KMT2AMEN1KDM4E | |
| SCHEMBL15337692 | 0.79 | ALDH1A1 (0.58) | ALDH1A1NPC1KMT2AMEN1PHGDH | |
| SCHEMBL23984141 | 0.78 | ALDH1A1 (0.49) | ALDH1A1NPC1KMT2AMEN1KDM4E | |
| SCHEMBL10282539 | 0.78 | ALDH1A1 (0.67) | ALDH1A1NPC1KMT2AMEN1PHGDH | |
| SCHEMBL13422266 | 0.77 | HTR1A (0.46) | ALDH1A1NPC1DPP4KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368930-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368930-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885NPC1 2113/4885DPP4 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.